Bionomics Ltd.’s drug candidate, BNC-210 would be advanced into Phase 3 studies in Social Anxiety Disorder (SAD) after the successful End-of-Phase 2 Meeting with the U.S. FDA in September. BNC-210 has a unique action potential that depends on acetylcholine neurotransmission and allosteric modulation of α7 nAChR. It is designed to treat patients with serious central nervous system (CNS) disorders with limited side effects. BNC-210 received Fast-Track designation from the FDA for the acute treatment of SAD.